Navigation Links
Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline
Date:2/19/2013

S-TTRRx on neurological dysfunction and on quality-of-life.  The United States Food and Drug administration granted ISIS-TTRRx fast track designation and orphan drug status for the treatment of FAP.

"The rapid development of ISIS-TTRRx from a research-stage program to a drug in late-stage clinical development in just over two years represents the strong commitment of both teams to bring this novel drug to patients who are in need of new therapeutic options," said B. Lynne Parshall , chief operating officer at Isis.  "The encouraging data from our Phase 1 study, in which our drug was well tolerated and produced significant reductions in TTR protein, supported the advancement of ISIS-TTRRx directly into this registration-directed Phase 2/3 study.  While we will continue to manage the clinical development of ISIS-TTRRx, we will benefit from GSK's late-stage clinical development, regulatory and commercial expertise."

ISIS-TTRRx is part of the Isis-GSK strategic alliance to develop RNA therapeutics for rare and infectious diseases.  For the initiation of the Phase 2/3 study, Isis will receive a $7.5 million milestone payment and is eligible to earn an additional $50 million in pre-licensing milestone payments to support the Phase 2/3 study of ISIS-TTRRx­.  In addition, Isis is eligible to receive regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.

ABOUT ISIS-TTRRx
Transthyretin amyloidosis is a genetic disease in which the patient inherits a mutant gene that produces a misfolded form of TTR, which progressively accumulates in tissues, impairing their function.  In patients with transthyretin amyloidosis, both the mutant and normal forms of TTR can build up as fibrils in tissues, including heart, peripheral nerves, and the gastrointestinal tract.&
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
2. Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
3. NW Bio Takes Next Steps In Moving Forward With Its Phase III Brain Cancer Trial In Europe
4. Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
5. RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
6. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
7. Matrixx Initiatives Withdraws Acquisition Offer for ProPhase Labs
8. Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
9. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
10. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
11. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... N.J. and FARMINGTON, Conn. ... Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company ... of diseases with significant unmet medical need and ... on a private placement of 2,050,000 shares of ... purchase 24,949,325 shares of its common stock.  Funds ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... 2007 - Enzon,Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today ... at the 2007,Annual Meeting of the American Association ... 14 - 18, 2007 in Los Angeles, CA., ... -- Abstract #1494: EZN-2208, a novel polyethyleneglycol-SN38,conjugate, has ...
... 13, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today,announced that ... Meeting,of the American Association for Cancer Research (AACR) ... , Data being presented in a poster session ... selective and potent,inhibitor of cyclin-dependent kinases (CDKs) 2, ...
Cached Medicine Technology:Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting 2Sunesis Pharmaceuticals to Present Data at the Annual Meeting of,the American Association for Cancer Research 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... , Effort aims to ... and professionals and pursue a co-operative and collaborative approach to ... , WASHINGTON, Aug. 4 The National ... a formal Memorandum of Understanding with two like-minded organizations--the Canadian ...
... , INDIANAPOLIS, Aug. 4 Arcadia Resources, Inc. ... innovative consumer health care services under the Arcadia HealthCare(SM) brand, ... provider Comfort Keepers((R) )to provide DailyMed(TM) for Comfort Keepers franchisees ... the program with Comfort Keepers will launch this month and ...
... , , , GLENWOOD, ... a recognized leader in personal and environmental radiation monitoring services, today reported financial ... , , Fiscal 2009 Third Quarter Highlights , ... to $23.5 million on continued global demand for InLight products and increased domestic ...
... , , CARLSBAD, Calif., Aug. ... leader in antisense therapeutics, today announced that management will present a ... on Tuesday, August 11, 2009, at 1:00 p.m. ET at the ... webcast of the presentation will be available on the "Investors & ...
... , , , ... GOHE) is pleased to advise the nutrition and investing community that ... Releases and corporate activities, are easily accessible by simply Googling Cholesterade(R). ... searching for recent updates on Go Healthy and/or its products, we ...
... , , HUNTINGTON ... sports water , is targeting the Southern California ... events throughout the late summer and fall. , ... the most demanding environments, from professional sporting events to serious amateur ...
Cached Medicine News:Health News:The National Health Care Anti-Fraud Association Signs Memorandum of Understanding With Canadian and European Anti-Fraud Organizations 2Health News:The National Health Care Anti-Fraud Association Signs Memorandum of Understanding With Canadian and European Anti-Fraud Organizations 3Health News:Arcadia HealthCare's DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care 2Health News:Arcadia HealthCare's DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care 3Health News:Arcadia HealthCare's DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care 4Health News:Arcadia HealthCare's DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care 5Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 2Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 3Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 4Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 5Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 6Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 7Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 8Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 9Health News:Go Healthy's Marquis Product Cholesterade(R) at Your Fingertips on Google 2Health News:AquaHydrate, First High Performance Sports Water, Targets So Cal Sports Market With Summer Event Support 2Health News:AquaHydrate, First High Performance Sports Water, Targets So Cal Sports Market With Summer Event Support 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: